Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from ... CagriSema combines semaglutide, the active ingredient in Wegovy that mimics gut hormone GLP-1, with a separate ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab ... CagriSema combines semaglutide, the active ingredient in Wegovy that mimics gut hormone GLP-1, with a separate ...

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Novo Nordisk’s growth prospects for its semaglutide medicines presently appear to be at risk. Medicare has selected NVO’s semaglutide medicines for the second round of price negotiations in 2025.